Eribulin Pregnancy and Breastfeeding Warnings
Eribulin is also known as: Halaven
Eribulin Pregnancy Warnings
Animal studies have revealed evidence of fetal harm including embryofetal death, abortion, reduced fetal weight, minor skeletal anomalies, and severe external or soft tissue malformations such as the absence of a lower jaw, tongue, stomach, and spleen. Maternotoxicity has occurred in rats at or above the recommended human dose including splenomegaly, reduced maternal weight gain, and decreased food consumption.
Eribulin has been assigned to pregnancy category D by the FDA. Animal studies have revealed evidence of embryofetal toxicity and teratogenicity. There are no controlled data in human pregnancy. If eribulin is used during pregnancy, or if the patient becomes pregnant while receiving this drug, the patient should be apprised of the potential hazard to the fetus.
Eribulin Breastfeeding Warnings
The manufacturer recommends that due to the potential for serious adverse reactions in nursing infants, a decision should be made to discontinue nursing or discontinue the drug, taking into account the benefit of breast-feeding to the infant and the importance of the drug to the mother. There are no data on the excretion of eribulin into human milk. The effects in the nursing infant are unknown.
See Also...
- eribulin Consumer Information
- Pregnancy Support Group
- FDA Pregnancy Categories
- Medicine use during Pregnancy
- Medicine use while Breastfeeding
- Safe Medications during Breastfeeding
Disclaimer: Every effort has been made to ensure that the information provided by Cerner Multum, Wolters Kluwer Health and Drugs.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. In addition, the drug information contained herein may be time sensitive and should not be utilized as a reference resource beyond the date hereof. This drug information does not endorse drugs, diagnose patients, or recommend therapy. This drug information is a reference resource designed as supplement to, and not a substitute for, the expertise, skill , knowledge, and judgement of healthcare practitioners in patient care. The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug of drug combination is safe, effective, or appropriate for any given patient. Multum Information Services, Inc. does not assume any responsibility for any aspect of healthcare administered with the aid of information Multum provides. Copyright 2000-2008 Multum Information Services, Inc. The information in contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse, or pharmacist.
